Pfizer Inc. (NYSE:PFE) Stake Raised by State of Alaska Department of Revenue

State of Alaska Department of Revenue boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 796,553 shares of the biopharmaceutical company's stock after acquiring an additional 17,820 shares during the quarter. State of Alaska Department of Revenue's holdings in Pfizer were worth $20,184,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Lipe & Dalton raised its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 400 shares in the last quarter. Beam Wealth Advisors Inc. lifted its stake in Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after purchasing an additional 401 shares during the last quarter. Providence Capital Advisors LLC lifted its position in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after purchasing an additional 409 shares during the last quarter. Donaldson Capital Management LLC raised its holdings in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after buying an additional 410 shares during the last quarter. Finally, Noesis Capital Mangement Corp grew its stake in shares of Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after purchasing an additional 413 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Down 1.6%

Shares of PFE stock opened at $24.00 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market cap of $136.47 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.89 and a beta of 0.57. The company has a 50 day simple moving average of $23.14 and a two-hundred day simple moving average of $24.93.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the business posted $0.82 EPS. Pfizer's revenue was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.17%. The ex-dividend date was Friday, May 9th. Pfizer's dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.